Jan Krönke

7.2k total citations · 3 hit papers
57 papers, 3.5k citations indexed

About

Jan Krönke is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Jan Krönke has authored 57 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Hematology, 42 papers in Molecular Biology and 14 papers in Oncology. Recurrent topics in Jan Krönke's work include Protein Degradation and Inhibitors (34 papers), Multiple Myeloma Research and Treatments (30 papers) and Ubiquitin and proteasome pathways (22 papers). Jan Krönke is often cited by papers focused on Protein Degradation and Inhibitors (34 papers), Multiple Myeloma Research and Treatments (30 papers) and Ubiquitin and proteasome pathways (22 papers). Jan Krönke collaborates with scholars based in Germany, United States and Slovenia. Jan Krönke's co-authors include Benjamin L. Ebert, Slater N. Hurst, Namrata D. Udeshi, Steven A. Carr, Dirk Heckl, Marie McConkey, Tanya Svinkina, Nikhil C. Munshi, Christie Ciarlo and Monica Schenone and has published in prestigious journals such as Science, New England Journal of Medicine and Nature Communications.

In The Last Decade

Jan Krönke

51 papers receiving 3.4k citations

Hit Papers

Lenalidomide Causes Selective Degradation of IKZF1 and IK... 2010 2026 2015 2020 2013 2010 2020 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
    2013 1.3k citations Jan Krönke, Namrata D. Udeshi et al. Science profile →
  2. IDH1andIDH2Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia WithNPM1Mutation WithoutFLT3Internal Tandem Duplication
    2010 578 citations Peter Paschka, Richard F. Schlenk et al. Journal of Clinical Oncology profile →
  3. Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
    2020 233 citations Christian Langer, Jan Krönke et al. Journal of Clinical Oncology profile →

Peers

Jan Krönke
David Taussig United Kingdom
Harald Herrmann Austria
Yazan Alsayed United States
Peter Grauman United States
Amanda L. Christie United States
Sylvie Freeman United Kingdom
Anjan Thakurta United States
Katharina Blatt Austria
Christopher P. Wardell United Kingdom
Catherine Pellat‐Deceunynck France
David Taussig United Kingdom
Jan Krönke
Citations per year, relative to Jan Krönke Jan Krönke (= 1×) peers David Taussig

Countries citing papers authored by Jan Krönke

Since Specialization
Citations

This map shows the geographic impact of Jan Krönke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Krönke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Krönke more than expected).

Fields of papers citing papers by Jan Krönke

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Krönke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Krönke. The network helps show where Jan Krönke may publish in the future.

Co-authorship network of co-authors of Jan Krönke

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Krönke. A scholar is included among the top collaborators of Jan Krönke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Krönke. Jan Krönke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Steinebach, Christian, et al.. (2025). PROTAC-Mediated GSPT1 Degradation Impairs the Expression of Fusion Genes in Acute Myeloid Leukemia. Cancers. 17(2). 211–211. 1 indexed citations
2.
Hoenicka, Markus, Andreas Liebold, Vadim Sakk, et al.. (2025). Functional and molecular analyses reveal impaired HSPCs in Multiple Myeloma patients post-induction. Stem Cells Translational Medicine. 14(11). 1 indexed citations
3.
Bricelj, Aleša, Martina Gobec, Thomas Geiger, et al.. (2025). Enhancing Solubility in VHL-Based PROTACs: Optimized USP7 Degraders for Improved Developability. Journal of Medicinal Chemistry. 68(15). 15711–15737.
4.
Blau, Igor Wolfgang, Olga Blau, Laura Rocchi, et al.. (2024). In vitro testing of drug response in primary multiple myeloma cells using a microwell-based technology. Leukemia Research. 147. 107599–107599.
5.
Bricelj, Aleša, Yuen Lam Dora Ng, Martina Gobec, et al.. (2024). Design, Synthesis, and Evaluation of BCL‐2 Targeting PROTACs. Chemistry - A European Journal. 30(45). e202400430–e202400430. 3 indexed citations
6.
Mi, Yang, Yichen Wang, Philipp Mertins, et al.. (2024). Failure to Execute Caspase Activation Drives Therapy Resistance in TP53 Mutated AML. Blood. 144(Supplement 1). 53–53.
7.
Ihlow, Jana, Michaela Schwarz, Anne Flörcken, et al.. (2024). Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy. Blood Cancer Journal. 14(1). 160–160. 2 indexed citations
8.
Wang, Zefeng, Shabnam Shaabani, Xiang Gao, et al.. (2023). Direct-to-biology, automated, nano-scale synthesis, and phenotypic screening-enabled E3 ligase modulator discovery. Nature Communications. 14(1). 8437–8437. 26 indexed citations
9.
Kuchta, Robert D., Yuen Lam Dora Ng, Izidor Sosič, et al.. (2023). Accessing three-branched high-affinity cereblon ligands for molecular glue and protein degrader design. RSC Chemical Biology. 4(3). 229–234. 4 indexed citations
10.
Ng, Yuen Lam Dora, Evelyn Ramberger, Stephan Bohl, et al.. (2022). Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. Nature Communications. 13(1). 1009–1009. 42 indexed citations
11.
Sosič, Izidor, et al.. (2022). Targeting the deubiquitinase USP7 for degradation with PROTACs. Chemical Communications. 58(63). 8858–8861. 36 indexed citations
12.
13.
Hegazy, Ahmed N., Jan Krönke, Stefan Angermair, et al.. (2022). Anti-SARS-CoV2 antibody-mediated cytokine release syndrome in a patient with acute promyelocytic leukemia. BMC Infectious Diseases. 22(1). 537–537. 6 indexed citations
14.
Ng, Yuen Lam Dora, Annika Scheffold, Stefanie Lindner, et al.. (2020). Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn. Experimental Hematology. 93. 61–69.e4. 3 indexed citations
15.
Lindner, Stefanie, et al.. (2019). Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs. Journal of Visualized Experiments. 13 indexed citations
16.
17.
18.
Krönke, Jan, Slater N. Hurst, & Benjamin L. Ebert. (2014). Lenalidomide induces degradation of IKZF1 and IKZF3. OncoImmunology. 3(7). e941742–e941742. 66 indexed citations
19.
Krönke, Jan, Namrata D. Udeshi, Anupama Narla, et al.. (2013). Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells. Science. 343(6168). 301–305. 1288 indexed citations breakdown →
20.
Paschka, Peter, Richard F. Schlenk, Verena I. Gaidzik, et al.. (2010). IDH1andIDH2Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia WithNPM1Mutation WithoutFLT3Internal Tandem Duplication. Journal of Clinical Oncology. 28(22). 3636–3643. 578 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David Taussig Breakdown of academic impact, for papers by Harald Herrmann Breakdown of academic impact, for papers by Yazan Alsayed Breakdown of academic impact, for papers by Peter Grauman Breakdown of academic impact, for papers by Amanda L. Christie Breakdown of academic impact, for papers by Sylvie Freeman Breakdown of academic impact, for papers by Anjan Thakurta Breakdown of academic impact, for papers by Katharina Blatt Breakdown of academic impact, for papers by Christopher P. Wardell Breakdown of academic impact, for papers by Catherine Pellat‐Deceunynck
Rankless by CCL
2026